Another ACL Success Story!

This will be a shorter blog this morning. I received a comment from a 2018 patient who had his knee treated with our Perc-ACLR procedure. All of that ties into the quote above.

The Comment

“Chris:

I am a testimonial to the effectiveness of this procedure. Over 2 1/2 years out and knee is doing well. I can ski bike and do most everything I did previously without difficulty. I highly endorse this procedure and the Regenexx clinic in general.”

Marc is a local chiropractor who injured his ACL in 2018 and had our Perc-ACLR procedure, which looks like this:

This procedure carefully placed Marc’s highly concentrated bone marrow stem cells into both bands of the damaged ACL ligament using fluoroscopy guidance. His 3-month images showed the start of healing and as you can see, he’s still doing well without ACL surgery, despite being an ACL surgical candidate.

Here are many before and after MRIs showing ACL healing after this procedure:

Learn More About Regenexx^® Procedures

Request a digital booklet and more information to learn about alternatives to orthopedic surgery and the Regenexx patient experience.

Your Email *

Include the weekly newsletter. It's free and you can unsubscribe at any time.

Submit

We do not sell, or share your information to third party vendors. By submitting the form you agree that you've read and consent to our Privacy Policy.

A Word of Technological Disruption

ACL surgery is a huge industry. Here are a smattering of existing players who benefit greatly by keeping patients flowing toward ACL surgery:

• Surgeons
• Surgical assistants
• Hospitals and surgery centers
• Device and equipment manufacturers of ACL specific hardware
• Device manufacturers who manufacture surgical imaging equipment and tools (scopes)
• Sales Reps for device manufacturers

Hence, what would happen if 2/3rds of the patients who now get surgery, got a precise x-ray guided injection instead and got to keep their own repaired ACL? Patients would surely benefit from less invasive care and much quicker recovery, but all of the players above would experience a net negative shock to their bottom lines. Now let’s look at who benefits from this tech disruption:

• Patients
• Insurers
• Employers

Hence, that’s why Regenexx has been focusing primarily on patients and employers with our corporate program. We are making tremendous strides year over year in getting these procedures fully covered by employers. Insurers will be our last target, just because institutional momentum is huge in huge organizations.

The upshot? If you’re on the top list, this IS coming your way. Retooling and refocusing on how to earn money by moving patients from surgery to precise injections would be wise. If you’re on the bottom list, big savings and new tech is coming your way. Again, as Mr. Christensen has said, don’t get stuck in a business model or thought process and miss the opportunities that come with change.

Chris Centeno, MD is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications. View Profile